Back

Clinical outcomes of intermittent or outpatient intravenous levosimendan therapy in advanced chronic heart failure: a systematic review

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Managing acute heart failure and the end-stage bridge Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Rubiya Ali

Memorial Healthcare System, Pembroke Pines (United States of America)

5 More presentations in this session

Presentation thumbnail
Early prediction of prolonged length of stay in heart failure admissions using machine learning models
Mrs X. Zalazar (Atlanta, US)
Abstract Slides Video
Presentation thumbnail
Cardiac contractility modulation vs guideline-directed medical therapy in symptomatic HFrEF with narrow QRS: an updated systematic review and meta-analysis
Doctor R. Ali (Pembroke Pines, US)
Presentation thumbnail
Stratifying response to omecamtiv mecarbil in HFrEF using multiscale cardiac digital twins
Doctor E. Casoni (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
A systematic review and meta-analysis of cardiology-led care Vs general medical care in hospitalised acute decompensated heart failure patients: effects on in-hospital mortality and 30-day readmission
Ms M. Walshe (Kilkenny, IE)
Abstract Slides Video
Presentation thumbnail
STOP-DHF (a non-invasive hemodynamic-guided strategy to prevent heart failure decompensation) trial: preliminary results of medical therapy interventions study
Associate Professor A. Bohm (Bratislava, SK)
Abstract Slides Video

Access the full session

Session thumbnail
Managing acute heart failure and the end-stage bridge

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Presentation
The early use of inotropes, BB, SGLT2-i, ARNI and MRA in acute heart failure: the PENTA-HF observational study
thumbnail
Congress Presentation
The experience of more than three hundred levosimendan administrations: what we have learned
thumbnail
Congress Presentation
Intermittent levosimendan in advanced palliative heart failure improves quality of life and reduces heart failure decompensations: a single center-experience

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources